公开(公告)号：US11643464B2

公开(公告)日：2023-05-09

申请号：US16728587

申请日：2019-12-27

Applicant: Yeda Research and Development Co. Ltd

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K39/395 ,  A61P27/02 ,  A61K45/06 ,  A61K31/404 ,  A61K31/7068 ,  A61K31/4155 ,  A61K33/36 ,  A61K39/00

CPC classification number: C07K16/2818 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K39/395 ,  A61K39/39541 ,  A61K45/06 ,  C07K16/2803 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/572 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/76 ,  A61K33/36 ,  A61K2300/00 ,  A61K31/404 ,  A61K2300/00 ,  A61K31/4155 ,  A61K2300/00 ,  A61K31/7068 ,  A61K2300/00

Abstract: The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

公开(公告)号：US20220146534A1

公开(公告)日：2022-05-12

申请号：US17423769

申请日：2020-01-16

Applicant: Yeda Research and Development, Co., Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Hila Ben-Yehuda ,  Michal Arad ,  Tommaso Croese ,  Javier Maria Peralta Ramos ,  Giulia Castellani ,  Neta Rosenzweig

IPC: G01N33/68 ,  G01N33/50

Abstract: A method for predicting whether a patient diagnosed with a disease, disorder, condition or injury of the CNS is likely to be responsive or non-responsive to treatment with an immune checkpoint modulator is provided, wherein said method comprises determining ex vivo, in a blood sample obtained from the patient, or in a fraction thereof, a biomarker selected from: (a) the level of a monocyte subpopulation expressing CCR2, CD204 or a combination thereof, or CCR2 and a marker selected from igf1, lyve1, Stab-1, Siglec1 and Mrc1, or any combination thereof, (b) the ratio of the level of a monocyte subpopulation (CD14+ cells) expressing CCR2highCX3CR1low to a monocyte subpopulation expressing CCR2lowCX3CR1high; (c) the level of a CCR2 agonist; and (d) the level of a CCR2 antagonist.

公开(公告)号：US20190185563A1

公开(公告)日：2019-06-20

申请号：US16284081

申请日：2019-02-25

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K38/02 ,  A61K38/00 ,  A61K31/4155 ,  A61K38/16 ,  A61K38/18 ,  A61K38/20 ,  A61K38/14 ,  A61K45/06 ,  A61K31/404 ,  A61K39/395 ,  A61K33/36 ,  A61K31/7068

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

公开(公告)号：US20180111999A1

公开(公告)日：2018-04-26

申请号：US15821678

申请日：2017-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K45/06 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/02 ,  A61K38/14 ,  A61K38/16 ,  A61K38/18 ,  A61K38/20 ,  A61K31/404 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

公开(公告)号：US20180111998A1

公开(公告)日：2018-04-26

申请号：US15821672

申请日：2017-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K45/06 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/14 ,  A61K38/16 ,  A61K38/18 ,  A61K31/404 ,  A61K39/395 ,  A61K38/20 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

公开(公告)号：US10961309B2

公开(公告)日：2021-03-30

申请号：US16167226

申请日：2018-10-22

Applicant: Yeda Research and Development Co. Ltd

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K39/395 ,  A61K38/00 ,  A61K38/14 ,  A61K45/06 ,  A61K31/404 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/16 ,  A61K38/18 ,  A61K38/20 ,  A61K31/4155 ,  A61K38/02 ,  A61K39/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

公开(公告)号：US20190112371A1

公开(公告)日：2019-04-18

申请号：US16167226

申请日：2018-10-22

Applicant: Yeda Research and Development Co. Ltd

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K38/02 ,  A61K38/00 ,  A61K31/4155 ,  A61K38/16 ,  A61K38/18 ,  A61K38/20 ,  A61K38/14 ,  A61K45/06 ,  A61K31/404 ,  A61K39/395 ,  A61K33/36 ,  A61K31/7068

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

公开(公告)号：US10214585B2

公开(公告)日：2019-02-26

申请号：US14850794

申请日：2015-09-10

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K39/395 ,  A61K38/00 ,  A61K31/4155 ,  A61K38/16 ,  A61K38/18 ,  A61K38/20 ,  A61K38/14 ,  A61K45/06 ,  A61K31/404 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/02 ,  A61K39/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.

公开(公告)号：US09982047B2

公开(公告)日：2018-05-29

申请号：US15821570

申请日：2017-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K38/18 ,  A61K38/14 ,  A61K38/00 ,  A61K38/20 ,  A61K33/36 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K38/16 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

公开(公告)号：US09534052B2

公开(公告)日：2017-01-03

申请号：US15212231

申请日：2016-07-16

Applicant: Yeda Research and Development Co. Ltd

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: C07K16/28 ,  A61K38/00 ,  A61K31/4155 ,  A61K39/395 ,  A61K38/16 ,  A61K38/18 ,  A61K38/20 ,  A61K38/14 ,  A61K45/06 ,  A61K31/404 ,  A61K31/7068 ,  A61K33/36 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/7068 ,  A61K33/36 ,  A61K38/00 ,  A61K38/005 ,  A61K38/02 ,  A61K38/14 ,  A61K38/168 ,  A61K38/18 ,  A61K38/208 ,  A61K39/395 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2121/00 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

Abstract translation: 一种包含活性剂的药物组合物，其引起个体中用于治疗不包括自身免疫性神经炎症性疾病，复发性多发性硬化症（RRMS）的疾病，病症，病状或损伤的个体的全身免疫抑制水平的降低 ）。 药物组合物用于通过包含至少两个治疗疗程的剂量方案给药，每个治疗过程依次包括治疗会话，随后是间隔期。